Cepheid stock has been delisted and is no longer actively trading. Cepheid is now a division of Danaher Corporation (NYSE:DHR). NASDAQ:CPHD Cepheid (CPHD) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Cepheid Stock (NASDAQ:CPHD) 30 days 90 days 365 days Advanced Chart Get Cepheid alerts:Sign Up Key Stats Today's Range$52.95▼$52.9550-Day Range N/A52-Week Range$25.09▼$53.91VolumeN/AAverage Volume1.25 million shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewCepheid is a molecular diagnostics company. The Company develops, manufactures and markets fully-integrated systems for testing in the Clinical and Non-Clinical markets. The Company's systems enable molecular testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. The Company's systems integrate these steps and analyze biological samples in test cartridges. Its primary offering is the GeneXpert system, which integrates sample preparation in addition to Deoxyribonucleic acid (DNA) amplification and detection. The GeneXpert system is designed for a range of user types ranging from reference laboratories and hospital central laboratories to satellite testing locations, such as emergency departments and intensive care units within hospitals, as well as physician offices and other alternate site laboratories. It also offers the SmartCycler system, which integrates DNA amplification and detection to allow rapid analysis of a sample.Read More… Receive CPHD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cepheid and its competitors with MarketBeat's FREE daily newsletter. Email Address CPHD Stock News HeadlinesOxford Nanopore and Cepheid Collaborate on Sequencing SolutionsApril 9, 2025 | tipranks.comIn The Fight To End Tuberculosis, This Is The Moment For ProgressNovember 15, 2023 | forbes.comTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.May 3, 2025 | Porter & Company (Ad)Reducing the spread of hepatitis CJuly 22, 2023 | bbc.comSpotSee Forms Life Science Advisory Council with Global Industry LeadersJune 27, 2023 | it.tmcnet.comCepheid (CPHD) Showing Signs Of Being Water-Logged And Getting WetterMay 14, 2023 | thestreet.comGlobal Biochips Market Research Report 2022: Market to Surpass $25+ Billion by 2026 - ResearchAndMarkets.com - Business WireOctober 13, 2022 | businesswire.comThe Worldwide Infectious Disease In Vitro Diagnostics Industry is Expected to Reach $56.6 Billion by 2030 - ResearchAndMarkets.com - Business WireOctober 7, 2022 | businesswire.comSee More Headlines CPHD Stock Analysis - Frequently Asked Questions How were Cepheid's earnings last quarter? Cepheid (NASDAQ:CPHD) released its quarterly earnings results on Thursday, July, 28th. The scientific and technical instruments company reported $0.05 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.14) by $0.19. Cepheid's revenue for the quarter was up 10.2% on a year-over-year basis. What other stocks do shareholders of Cepheid own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cepheid investors own include Editas Medicine (EDIT), Nokia Oyj (NOK), Bristol-Myers Squibb (BMY), GE Aerospace (GE), Gilead Sciences (GILD), QUALCOMM (QCOM) and AK Steel (AKS). Company Calendar Last Earnings7/28/2016Today5/03/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorN/A Industry N/A Sub-IndustryBiotechnology Current SymbolNASDAQ:CPHD CIK1037760 Webwww.cepheid.com Phone+1-408-5414191FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free Report This page (NASDAQ:CPHD) was last updated on 5/3/2025 by MarketBeat.com Staff From Our PartnersThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | SponsoredHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredTrump to solve American wealth loss?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredThe collapse has already startedThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cepheid Please log in to your account or sign up in order to add this asset to your watchlist. Share Cepheid With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.